Johnson & Johnson MedTech (NYSE: JNJ) today announced the first completed commercial case with its Varipulse platform in ...

The article " Johnson & Johnson Stock: Setting the Stage for 2025 Highs " first appeared on MarketBeat.

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson has been a stalwart dividend stock over the years because it has maintained a healthy financial profile, ...

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...